CibusCBUS
CBUS
About: Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Employees: 159
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
211% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 9
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
16% more funds holding
Funds holding: 57 [Q3] → 66 (+9) [Q4]
1.65% more ownership
Funds ownership: 34.1% [Q3] → 35.75% (+1.65%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
10% less capital invested
Capital invested by funds: $29.1M [Q3] → $26.3M (-$2.82M) [Q4]
68% less call options, than puts
Call options by funds: $13K | Put options by funds: $40K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$25
1,063%
upside
Avg. target
$25
1,063%
upside
High target
$25
1,063%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Amit Dayal 22% 1-year accuracy 27 / 121 met price target | 1,063%upside $25 | Buy Reiterated | 21 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
5 days ago
Cibus to Report First Quarter 2025 Financial Results on May 8, 2025 After the Market Close and Host Conference Call
SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2025 financial results on Thursday, May 8, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.
Neutral
GlobeNewsWire
6 days ago
USDA-APHIS Designates Additional Cibus' Disease Resistance Trait Products as Not Regulated
Designation confirms conventional regulation of Cibus traits in the U.S. as modernized regulatory policy for precision gene editing breeding technologies continues to advance globally Designation confirms conventional regulation of Cibus traits in the U.S. as modernized regulatory policy for precision gene editing breeding technologies continues to advance globally
Neutral
Seeking Alpha
1 month ago
Cibus, Inc. (CBUS) Q4 2024 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Carlo Broos - Interim Chief Financial Officer Peter Beetham - Co-Founder, President and COO, Interim CEO Greg Gocal - Co-Founder and Chief Scientific Officer and Executive Vice President Conference Call Participants Laurence Alexander - Jefferies Austin Moeller - Canaccord Sameer Joshi - H. C. Wainwright Matthew Venezia - Alliance Global Partners Operator Good afternoon, and welcome to the Cibus Fourth Quarter 2024 Results Conference Call.
Neutral
GlobeNewsWire
1 month ago
Cibus Reports Fourth Quarter Financial Results and Provides Business Update
A major milestone on March 14th 2025 advanced the EU Trilogue discussions aimed to complete the final text of the New Genomic Techniques (NGTs) or gene editing legislation for the EU; California Rice Commission approved Cibus' field research proposal marking the first time gene edited Rice has been authorized for planting within the state
Neutral
GlobeNewsWire
1 month ago
Cibus Welcomes the European Union's Progress as Legislation for New Genomic Techniques to Boost Innovation and Sustainability Moves Forward
Legislation aims to adapt EU law to reflect scientific and technological progress, enabling the products of New Genomic Techniques (NGTs), such as gene editing, to contribute to more sustainable agriculture, climate resilience, and food security Proposed legislation identifies a ‘conventional-like' category of NGT-1 products that would be regulated as conventional varieties, bringing EU regulation closer to that of other global trading partners The agreement on the Council's negotiating mandate allows its presidency to start negotiations with the European Parliament on the final text of the regulation SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies, welcomes significant progress in the regulation of New Genomic Techniques (NGTs) in the European Union (EU). On Friday 14th March, EU member states endorsed the EU Council's (the “Council”) negotiating mandate on the regulation of plants obtained by NGTs.
Neutral
GlobeNewsWire
1 month ago
Cibus to Report Fourth Quarter 2024 Financial Results on March 20, 2025 After the Market Close and Host Conference Call
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2024 financial results on Thursday, March 20, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.
Neutral
GlobeNewsWire
1 month ago
Cibus' Achieves Another Milestone for a Durable White Mold (Sclerotinia) Resistance Trait in Canola
Initial bioassay data for Cibus' third mode of action for white mold (Sclerotinia) resistance trait in canola shows promising results in controlled environment assessment
Neutral
GlobeNewsWire
2 months ago
Cibus Announces Leadership Change and CEO Succession Plan
SAN DIEGO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced key leadership changes pursuant to the Company's succession planning strategy. The Board has accepted Rory Riggs' resignation as the Company's Chief Executive Officer. Peter Beetham, the Company's President and Chief Operating Officer, also will serve as the Company's Interim Chief Executive Officer. Dr. Beetham is a co-founder of Cibus Global with Mr. Riggs and with Greg Gocal, who will remain the Company's Chief Scientific Officer. Mr. Riggs will remain Chairman of the Board of Directors. Dr. Beetham also will continue as a director.
Neutral
GlobeNewsWire
2 months ago
Cibus Announces Important Update to Rice Gene Editing Conversion Rates
SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today issued a correction relating to the rice conversion rates previously disclosed in its January 16, 2025 press release. The Company has concluded that the gene editing conversion rates of 10-25% in Rice have not been reconfirmed based upon subsequent experiments and high variability in the conversion rate data.
Neutral
GlobeNewsWire
3 months ago
Cibus to Participate in the Sidoti Micro Cap Conference
SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer, will host a presentation at the Sidoti Micro Cap Conference.
Charts implemented using Lightweight Charts™